Close Menu

NEW YORK – Lantern Pharma on Thursday said it has priced a public offering of 4,285,715 shares of its common stock at $14.00 per share.

Dallas, Texas-headquartered Lantern expects to raise gross proceeds of $60 million, minus underwriting discounts and offering expenses. The precision oncology firm has granted underwriters a 45-day option to purchase an additional 642,856 shares of common stock at the public offering price to cover over-allotments. The offering is slated to close on Jan. 20.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.